-
Infection and Drug Resistance
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles
Original Research
(3212) Views (744) Full article downloads
Authors: Somvadee Laohavaleeson, Karen Lolans, John P Quinn, Joseph L Kuti, David P Nicolau
Published Date November 2008
Volume 2008:1 Pages 51 - 55
DOI: http://dx.doi.org/10.2147/IDR.S4418
Somvadee Laohavaleeson1, Karen Lolans2,3, John P Quinn2,3,4, Joseph L Kuti1, David P Nicolau1
1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; 2John Stroger Hospital, Chicago, IL, USA; 3Chicago Infectious Disease Research Institute, Chicago, IL, USA; 4Rush University Medical Center, Chicago, IL, USA
Abstract: While MIC distributions and percent susceptibility for cefepime and ceftazidime are generally similar among Pseudomonas aeruginosa, we noted an increasing discordance in susceptibility favoring ceftazidime at our hospital. Quantitative reverse transcriptase-polymerase chain reaction was utilized to explore overexpression of the MexXY-OprM efflux as the mechanism for this phenotype profile. Thirteen of 15 (87%) randomly selected isolates had mexY gene expression levels of 5.8–40.8-fold relative to the wild-type reference strain. While mexY overexpression was noted in the majority of isolates, other resistance mechanisms appear to contribute to the observed phenotypic profile of the Pseudomonas aeruginosa studied. Clinicians must understand not only the magnitude of difference in the MIC profiles between agents, but also the mechanism(s) responsible for these observations if strategies (ie, pharmacodynamic dosing) are to be designed to optimize patient care outcomes in the face of increasing resistance.
Keywords: Pseudomonas aeruginosa, efflux, MexXY-OprM, mexY, cefepime, resistance
Readers of this article also read:
Characterization and antibiotic susceptibility of Listeria monocytogenes isolated from poultry and red meat in Morocco
High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Treatment of drug-resistant tuberculosis
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India




